Klaus Früh visits the Incubator to discuss his career and his work on cytomegalovirus-vectored vaccines which are unique in their ability to persistently maintain an immune shield of effector memory T cells, including highly unconventional MHC-II and MHC-E restricted CD8+ T cells.